Switch theme
Sign up to access all valuation multiples
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
2017
142
LTM Revenue $55.3M
LTM EBITDA -$30.7M
$216M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aquestive Therapeutics has a last 12-month revenue of $55.3M and a last 12-month EBITDA of -$30.7M.
In the most recent fiscal year, Aquestive Therapeutics achieved revenue of $57.6M and an EBITDA of -$26.6M.
Aquestive Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aquestive Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $50.6M | $57.6M | XXX | XXX | XXX |
| Gross Profit | $28.3M | $29.8M | XXX | XXX | XXX |
| Gross Margin | 56% | 52% | XXX | XXX | XXX |
| EBITDA | $1.2M | -$26.6M | XXX | XXX | XXX |
| EBITDA Margin | 2% | -46% | XXX | XXX | XXX |
| Net Profit | -$54.4M | -$7.9M | XXX | XXX | XXX |
| Net Margin | -108% | -14% | XXX | XXX | XXX |
| Net Debt | $24.9M | $3.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Aquestive Therapeutics's stock price is $3.
Aquestive Therapeutics has current market cap of $249M, and EV of $216M.
See Aquestive Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $216M | $249M | XXX | XXX | XXX | XXX | $-0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Aquestive Therapeutics has market cap of $249M and EV of $216M.
Aquestive Therapeutics's trades at 3.9x LTM EV/Revenue multiple, and -7.0x LTM EBITDA.
Analysts estimate Aquestive Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aquestive Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $216M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | -8.1x | XXX | XXX | XXX |
| P/E | -5.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -6.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAquestive Therapeutics's NTM/LTM revenue growth is 0%
Aquestive Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Aquestive Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aquestive Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aquestive Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -46% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -2352% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -46% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 35% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 122% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aquestive Therapeutics acquired XXX companies to date.
Last acquisition by Aquestive Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aquestive Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aquestive Therapeutics founded? | Aquestive Therapeutics was founded in 2017. |
| Where is Aquestive Therapeutics headquartered? | Aquestive Therapeutics is headquartered in United States of America. |
| How many employees does Aquestive Therapeutics have? | As of today, Aquestive Therapeutics has 142 employees. |
| Who is the CEO of Aquestive Therapeutics? | Aquestive Therapeutics's CEO is Mr. Daniel Barber. |
| Is Aquestive Therapeutics publicy listed? | Yes, Aquestive Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aquestive Therapeutics? | Aquestive Therapeutics trades under AQST ticker. |
| When did Aquestive Therapeutics go public? | Aquestive Therapeutics went public in 2018. |
| Who are competitors of Aquestive Therapeutics? | Similar companies to Aquestive Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aquestive Therapeutics? | Aquestive Therapeutics's current market cap is $249M |
| What is the current revenue of Aquestive Therapeutics? | Aquestive Therapeutics's last 12-month revenue is $55.3M. |
| What is the current EBITDA of Aquestive Therapeutics? | Aquestive Therapeutics's last 12-month EBITDA is -$30.7M. |
| What is the current EV/Revenue multiple of Aquestive Therapeutics? | Current revenue multiple of Aquestive Therapeutics is 3.9x. |
| What is the current EV/EBITDA multiple of Aquestive Therapeutics? | Current EBITDA multiple of Aquestive Therapeutics is -7.0x. |
| What is the current revenue growth of Aquestive Therapeutics? | Aquestive Therapeutics revenue growth between 2023 and 2024 was 14%. |
| Is Aquestive Therapeutics profitable? | Yes, Aquestive Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
